The stock of Black Diamond Therapeutics Inc (BDTX) has seen a -12.79% decrease in the past week, with a 9.24% gain in the past month, and a 14.90% flourish in the past quarter. The volatility ratio for the week is 7.16%, and the volatility levels for the past 30 days are at 7.46% for BDTX. The simple moving average for the last 20 days is 3.67% for BDTX stock, with a simple moving average of 39.25% for the last 200 days.
Is It Worth Investing in Black Diamond Therapeutics Inc (NASDAQ: BDTX) Right Now?
Company’s 36-month beta value is 2.52.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BDTX is 42.70M, and currently, short sellers hold a 6.13% ratio of that floaft. The average trading volume of BDTX on June 19, 2024 was 670.24K shares.
BDTX) stock’s latest price update
The stock of Black Diamond Therapeutics Inc (NASDAQ: BDTX) has decreased by -2.74 when compared to last closing price of 5.47. Despite this, the company has experienced a -12.79% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-01 that Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment
Analysts’ Opinion of BDTX
Stifel, on the other hand, stated in their research note that they expect to see BDTX reach a price target of $10, previously predicting the price at $2. The rating they have provided for BDTX stocks is “Buy” according to the report published on June 30th, 2023.
H.C. Wainwright gave a rating of “Buy” to BDTX, setting the target price at $11 in the report published on June 28th of the previous year.
BDTX Trading at -3.13% from the 50-Day Moving Average
After a stumble in the market that brought BDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.55% of loss for the given period.
Volatility was left at 7.46%, however, over the last 30 days, the volatility rate increased by 7.16%, as shares surge +8.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.56% lower at present.
During the last 5 trading sessions, BDTX fell by -12.79%, which changed the moving average for the period of 200-days by +57.86% in comparison to the 20-day moving average, which settled at $5.15. In addition, Black Diamond Therapeutics Inc saw 89.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BDTX starting from BIOTECH GROWTH N V, who purchase 400,000 shares at the price of $2.34 back on Oct 17 ’23. After this action, BIOTECH GROWTH N V now owns 8,517,839 shares of Black Diamond Therapeutics Inc, valued at $934,080 using the latest closing price.
Behbahani Ali, the Director of Black Diamond Therapeutics Inc, purchase 1,000,000 shares at $5.00 during a trade that took place back on Jul 05 ’23, which means that Behbahani Ali is holding 4,448,757 shares at $5,000,000 based on the most recent closing price.
Stock Fundamentals for BDTX
Current profitability levels for the company are sitting at:
- -17.4 for the present operating margin
- 0.63 for the gross margin
The net margin for Black Diamond Therapeutics Inc stands at -16.3. The total capital return value is set at -0.68. Equity return is now at value -78.81, with -57.38 for asset returns.
Based on Black Diamond Therapeutics Inc (BDTX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.77. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -124.12.
Currently, EBITDA for the company is -86.02 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 60.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.05.
Conclusion
In a nutshell, Black Diamond Therapeutics Inc (BDTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
